AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01989715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analyzing the position of the body, muscle activity
Study NCT02457598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously
Study NCT03740165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for pembrolizumab
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral tablet
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for olaparib
Description: Oral tablet
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for olaparib
Description: Oral tablet
Study NCT03740165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion
Study NCT01224561 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lipid overnutrition
Description: During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
Study NCT01594476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS
Description: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
Study NCT02065869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 T cells
Description: 1x10E6 cells/kg infused on Day 0
Study NCT02065869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: 0.4mg/kg administered IV to treat GVHD
Study NCT00006386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00006386 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00006386 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study NCT01704781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
Study NCT03113396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
Study NCT03113396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
Study NCT05336487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 2 hours of physical activity per day, 5 days per week, for the intervention period
Study NCT05529238 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: biofeedback training
Description: participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
Study NCT03221205 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
Study NCT03221205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Description: Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
Study NCT04511156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foundational Helping Skills
Description: Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
Study NCT02244762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours
Study NCT03740165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study NCT03947385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: IDE196 dosed orally, twice daily for each 28-day cycle
Study NCT00916214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Description: The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
Study NCT01158664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.6 mm tread pitch implant
Description: 0.6 mm tread pitch implant will be used
Study NCT01158664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.1 mm tread pitch implant
Description: 0.1 mm tread pitch implant will be used
Study NCT01315236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (LAI)
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension.
Study NCT01315236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.
Study NCT03947385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib dosed orally, twice daily for each 28-day cycle
Study NCT03947385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib dosed orally, twice daily for each 28-day cycle
Study NCT04255043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guidance
Description: IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
Study NCT04255043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guidance
Description: DCB (Sequent® Please) treatment
Study NCT02931630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein powder
Description: 60 g of whey protein powder
Study NCT02931630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin powder
Description: 60 g of Maltodextrin powder
Study NCT02931630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber bread
Description: Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
Study NCT01704781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide placebo
Description: Capsules are identical to the active Lenalidomide capsules used.
Study NCT02931630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber bread
Description: Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
Study NCT03658434 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
Study NCT04164030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Exercise Program for Adults with Type 2 Diabetes
Description: Eating Smart and Being Active program
Study NCT04164030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education plus Occupational Therapy plus Yoga
Description: multimodal interdisciplinary approach
Study NCT04483895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube insertion
Description: ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
Study NCT05493358 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic distal gastrectomy
Description: Distal gastrectomy and standard D2 lymphadenectomy
Study NCT03576053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine intradermal injection
Study NCT03196089 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Oxygen application
Description: Supplemental oxygen via mask
Study NCT03196089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen application
Description: Supplemental oxygen via mask
Study NCT04362254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study NCT04190446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04190446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT04190446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00696475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline
Study NCT00696475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00689091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
Study NCT00689091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic MAC alert
Description: Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
Study NCT02929784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
Study NCT01704781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-4X
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Study NCT02929784 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: no meaningful stimulation will be given.
Study NCT04728672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio Tape
Study NCT04728672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Micropore Tape
Description: Micropore Tape
Study NCT01759888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ
Description: Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study NCT03508427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily self-monitoring
Description: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
Study NCT00145678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy
Description: Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
Study NCT00145678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Community Care
Description: individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
Study NCT02625883 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Interview by validated Quality-of-life-questionnaire
Study NCT03899688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
Study NCT03899688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
Study NCT00797368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercise
Description: Manual Therapy and Exercise
Study NCT00797368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: Home exercises
Study NCT02644200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin tannate
Study NCT01182779 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion
Description: Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.
Study NCT01182779 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Protons
Description: Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.
Study NCT01704781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vacc-4X
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Study NCT01704781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant
Study NCT01704781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant
Study NCT03591796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOV
Description: Ventilated infants were randomized to HFOV
Study NCT03591796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMV
Description: Ventilated infants were randomized to CMV.
Study NCT04190446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00999128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose
Study NCT00999128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral repeating dose
Study NCT03481764 — intervention group
Intervention type: GENETIC
Intervention: HRC-test
Description: Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used.
Study NCT01564771 — intervention group
Intervention type: OTHER
Intervention: Non Intervention
Description: This Is A Non Interventional Study
Study NCT02821910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
Description: High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
Study NCT02821910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
Description: 1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
Study NCT01312350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant docetaxel/cisplatin/fluorouracil
Description: 2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
Study NCT01312350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No treatment before definitive CCRT
Description: concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
Study NCT00500045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinic acid
Description: niacin 1500 mg po qd
Study NCT00282165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naratriptan
Description: four weeks double blind experimental treatment using oral naratriptan
Study NCT00282165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: four weeks double blind placebo treatment
Study NCT02512263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based training program
Description: A home-based training program of 8 exercises to do 5 times a week during 9 weeks
Study NCT00798967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide
Description: 0.05 mg/kg/day sc injection for 24 weeks
Study NCT00798967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
Study NCT03576053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Skin Prick Test with Histamine
Study NCT03576053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Manually skin insertion of cowhage spicules
Study NCT03576053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stimulation
Description: Short heat stimulation
Study NCT03576053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heat stimulation
Description: Short heat stimulation
Study NCT03576053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-heating
Description: Mild skin pre-heating
Study NCT03576053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serotonin
Description: Serotonin electrophoresis
Study NCT04204590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Deprescribing algorithm
Description: For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.